Skip to main content
Marvel Biosciences Corp. logo

Marvel Biosciences Corp. — Investor Relations & Filings

Ticker · MRVL ISIN · CA57384M1077 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 203 across all filing types
Latest filing 2021-06-12 Interim / Quarterly Rep…
Country CA Canada
Listing TSXV MRVL

About Marvel Biosciences Corp.

https://marvelbiotechnology.com/

Marvel Biosciences Corp. is a pre-clinical stage biotechnology company specializing in the discovery and development of transformative treatments for complex neurological and neurodevelopmental disorders, including Autism Spectrum Disorder, Rett Syndrome, and Fragile X Syndrome. The company's core strategy involves chemical innovation to create synthetic derivatives of existing approved molecules. This drug redevelopment approach leverages established mechanisms to accelerate development and reduce risk. Its lead candidate, MB-204, is a patented synthetic derivative that has demonstrated preclinical efficacy across these target indications and is currently advancing toward first-in-human studies.

Recent filings

Filing Released Lang Actions
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'FORM 51-102F1 MANAGEMENT DISCUSSION AND ANALYSIS For the Nine Months Ended April 30, 2021' and contains detailed management discussion and analysis (MD&A) of the company's financial performance, liquidity, capital resources, and critical accounting estimates. It references unaudited interim financial statements for the nine months ended April 30, 2021 and audited financial statements for the year ended July 31, 2020. The content includes forward-looking statements, operating results, selected quarterly and annual financial information, and related party transactions. The document is comprehensive and contains substantive financial data and analysis for a period shorter than a full fiscal year (nine months). This matches the definition of an Interim / Quarterly Report (IR). It is not a brief announcement or a certification, nor is it a full annual report (10-K). Therefore, the correct classification is IR with high confidence.
2021-06-12 English
Interim financial statements/report – English.pdf
Regulatory Filings
2021-06-12 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a news release announcing the extension of the definitive agreement related to a Qualifying Transaction involving Alphanco Venture Corp. It discusses the extension of the closing date, financing conditions, and the nature of the transaction (an amalgamation and acquisition). There are no financial statements, detailed financial performance data, or comprehensive report content. The document is an announcement about a transaction and financing update rather than a full report or detailed financial disclosure. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is about 5,199 characters, which is consistent with an announcement rather than a full report.
2021-06-01 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a news release from Alphanco Venture Corp. announcing the receipt of disinterested shareholder approval related to amendments in company policy and escrow agreements. It discusses shareholder meeting resolutions and the company's plans to complete a Qualifying Transaction. There is no detailed financial data, no full report, and no transcript of a call. The document is an announcement of shareholder approval and related corporate actions, not a full report or filing. It fits best under Capital/Financing Update (CAP) because it relates to shareholder approvals affecting capital structure and transaction progress, specifically regarding a Qualifying Transaction and escrow amendments. The document length is over 5,000 characters and contains substantive information about corporate financing and shareholder approvals, not just a brief announcement or regulatory filing. Therefore, the classification is CAP with high confidence.
2021-04-19 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate, signed by the CEO certifying the accuracy and fair presentation of the interim financial report and interim MD&A for the period ended January 31, 2021. It is primarily an officer certification letter rather than the interim report itself. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR). The document length is under 5,000 characters and contains no substantive financial data or analysis, only the certification statement. Therefore, the correct classification is Regulatory Filings (RNS).
2021-03-22 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate by the CFO, certifying the review and fair presentation of the interim financial report and interim MD&A for the period ended January 31, 2021. It is primarily an officer certification letter confirming the accuracy and completeness of the interim filings, without containing actual financial statements or substantive financial data itself. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR) they reference. The document length is short (2981 characters), and it is clearly a certification rather than the report itself.
2021-03-22 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.